Anivance AI Participates in 2025 AACR Annual Meeting in Chicago

Together, we showcased New Approach Methodologies (NAMs) such as organ-on-chip platforms and CTC-derived organoid technologies, offering more predictive, ethical, and human-relevant tools for oncology research.

Throughout the exhibition, we received enthusiastic responses from researchers, clinicians, and industry leaders — all expressing a shared interest in moving beyond traditional animal models.

These technologies are strongly aligned with the FDA’s recent initiatives to accelerate adoption of human-based testing systems, supporting a shift toward smarter, faster, and more translational approaches in cancer drug development.

We believe that by advancing these tools, we can speed up discovery, increase clinical relevance, and ultimately bring hope to patients facing difficult-to-treat cancers.

Thank you to everyone who stopped by to engage with us — we’re excited for what’s ahead.